RG
MEDP icon

Redmile Group’s Medpace MEDP Stock Holding History

Redmile Group’s Portfolio MEDP Stock Details MEDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-499,640
Closed -$15.9M – 75
2017
Q3 		$15.9M Buy
499,640
+274,600
+122% +$8.39M 0.79% 37
2017
Q2 		$6.53M Buy
+225,040
New +$6.31M 0.4% 50

Other funds holding MEDP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCA
Bernzott Capital Advisors Camarillo, California $250M AUM 26.89% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Redmile Group's MEDP Position: Q4 2017 in Review

Redmile Group sold out of Medpace (MEDP) in Q4 2017, closing a stake of 499,640 shares — an estimated $15.9M sold.

Redmile Group first reported a position in MEDP in Q2 2017 and held it in 2 quarters. The position peaked at $15.9M in Q3 2017. 113 funds tracked by Wall St. Rank hold MEDP as of Q4 2017.

  • Redmile Group reported no remaining Medpace position as of Q4 2017 after selling out during the quarter.
  • Redmile Group sold 499,640 Medpace shares in Q4 2017, an estimated $15.9M.
  • Redmile Group first reported a position in Medpace in Q2 2017 and held it in 2 quarters.
  • Redmile Group's Medpace position peaked at $15.9M in Q3 2017.
  • 113 funds tracked by Wall St. Rank held Medpace as of Q4 2017.

Based on Redmile Group's 13F filing for Q4 2017, filed 14 Feb 2018.